mapk13 in 1

MAPK13-IN-1 is a potent MAPK13 (p38δ) inhibitor (IC50: 620 nM).

GnRH Associated Peptide (GAP) (1-13), human Acetate was found to be a potent inhibitor of prolactin secretion and to stimulate the release of gonadotropins. Active immunization with peptides corresponding to GAP sequences led to greatly increased prolacti

Dynorphin B (1-13) acetate acts as an agonist on opioid κ-receptor.

Apelin-13 triTFA is the endogenous ligand of the APJ receptor, activating this G protein-coupled receptor with an EC50 value of 0.37 nM.

Porcine dynorphin A(1-13) acetate (Dynorphin A Porcine Fragment 1-13 acetate) is a potent, endogenous κ opioid receptor agonist and is antinociceptive at physiological concentrations. Exposure to dynorphin A (1-13) causes acute increases in [Ca2+]i in individual neurons similar to increases seen with acute NMDA treatment.

[(pF)Phe4]Nociceptin(1-13)NH2 acetate is a selective agonist of NOP receptor with a pKi of 10.68 and a pEC50 of 9.31. [(pF)Phe4]Nociceptin(1-13)NH2 acetate displays high selectivity over δ, κ, and μ opioid receptors (>3000 fold).

Nociceptin (1-13), amide is a potent agonist Opioid receptor-like1 (ORL1) receptor with a pEC50 of 7.9 for mouse vas deferens and a Ki of 0.75 nM for binding to rat forebrain membranes.

p38-α MAPK-IN-1 is a MAPK14 (p38-α) inhibitor with an IC50 of 2300 nM in the EFC displacement assay and 5500 nM in the HTRF assay.

Galanin (1-13)-Neuropeptide Y (25-36) amide exhibits high-affinity binding to galanin receptors, comparable to that of galanin itself [1].

13-Acetoxy-3beta-hydroxygermacra-1(10)E,4E,7(11)-trien-12,6alpha-olide is a natural product from Artemisia myriantha.

Apelin-13 is an endogenous ligand of APJ receptor, and the EC 50 value of activated G protein coupled receptor is 0.37 nM.

[DAla2, DArg6] Dynorphin A, (1-13) (porcine) (DADAD), a derivative of dynorphin1-13 (DYN) extracted from porcine pituitary, exhibits high potency at peripheral opioid receptors GPI and MVD. Despite the rapid in vivo degradation of DYN, this compound shows increased resistance to enzymatic cleavage, enhancing its stability against peptide-degrading enzymes [1].

(Z)-docos-13-en-1-ol (Erucyl alcohol) is found in jojoba oil.

Enpp-1-IN-13 is an ectonucleotide pyrophosphatase/phosphodiesterase (ENPP) inhibitor that is able to act on ENPP1 (IC50: 1.29 μM) and ENPP3 (IC50: 20.2 μM), exhibiting anticancer effects.

Porcine dynorphin A (1-13), a potent endogenous κ opioid receptor agonist, exhibits antinociceptive properties at physiological concentrations and induces acute increases in [Ca2+]i in neurons, akin to those observed with acute NMDA treatment.

1, 14-tetradecanedioic-2, 2, 13, 13-d4 acid is a deuterated compound of 1, 14-tetradecanedioic acid. 1, 14-tetradecanedioic acid has a CAS number of 821-38-5. Tetradecanedioic acid is a C14 dicarboxylic acid.

Dynorphin B (1-13) TFA, an agonist of the opioid κ-receptor.

[Nphe1]Nociceptin(1-13)NH2 is a novel endogenous ligand for the nociceptin/orphanin FQ (NC) receptor, acting as a selective and competitive antagonist without any agonist effects. It binds specifically to recombinant nociceptin receptors with high affinity (pKi=8.4) and effectively blocks nociceptin's ability to inhibit cyclic AMP accumulation in CHO cells (pA2=6.0), showcasing potential as an analgesic agent.

Dynorphin A (1-13) amide, an endogenous opioid peptide, counteracts the analgesic effects of morphine [1].

Dynorphin B (1-13) acts as an agonist on the opioid κ-receptor.

Akt NF-κB MAPK-IN-1 (compound 2m) is a potent, orally active inhibitor of NO with an IC50 of 7.70 μM and low toxicity, exhibiting anti-inflammatory effects by blocking the Akt NF-κB and MAPK signaling pathways [1].

Compound (S)-9, a GLP-1 receptor agonist, exhibits an EC50 of 76 nM for the glucagon GLP-1 receptor [1].

8alpha-(2-Methylacryloyloxy)-1-O-methylhirsutinolide 13-O-acetate is a natural product for research related to life sciences. The catalog number is TN3293 and the CAS number is 883872-71-7.

Highly potent and selective nociceptin/orphanin FQ receptor (OP4) agonist peptide (pKi = 10.68; pEC50 = 9.80). Displays > 8000-fold selectivity over δ, κ, and μ opioid receptors and has relatively long lasting pronociceptive, hypotensive, negative inotrop

p38 MAPK-IN-1 displays sustained levels, low clearance, and good bioavailability. p38 MAPK-IN-1 is a novel effective and selective inhibitor of p38 MAPK (IC50: 68 nM).

Mcl-1 Inhibitor 13 (Example 9), with a Ki of 8.2 nM, serves as an MCL-1 inhibitor suitable for cancer research [1].

MAPK-IN-1 (Compound 2) is an inhibitor of the MAPK signaling pathway with anti-neuroinflammatory and neuroprotective activities, suitable for Alzheimer's disease research. It inhibits AChE with an IC50 of 23.84 μM [1].

CDK12 13-IN-1 (Compound 4) serves as an inhibitor of CDK12 13 and exhibits antitumor activity [1].

MMP-13-IN-1, with an IC50 value of 16 nM, is a potent and selective inhibitor of MMP-13, suitable for atherosclerosis research [1].

Parathyroid hormone (PTH) (1-13) is an N-terminal fragment of PTH (1-34) . In vivo, PTH (1-13) (0.003-1 μmol/kg) increases mean arterial pressure (MAP) in anesthetized rats.

TLR4 NF-κB MAPK-IN-1 is a novel antineuroinflammatory agent inhibiting the TLR4 NF-κB MAPK pathways.

HIV-1 inhibitor-13 is an orally active HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) with an IC50 value of 0.14 μM against HIV-1 RT. HIV-1 inhibitor-13 is active against HIV-1 resistant strains (EC50: 2.85-18.0 nM).

This peptide is a fragment of the alpha-chain of insulin amino acids 1 to 13. The insulin a-chain epitope recognized by human T cells is posttranslationally modified.

Polyketide synthase 13-IN-1 (compound 32) is an inhibitor of polyketide synthase 13.

Nociceptin (1-13), amide is a potent ORL1 (OP4) receptor agonist, exhibiting a pEC50 of 7.9 in mouse vas deferens and a Ki of 0.75 nM for rat forebrain membrane binding.

NF-κB/MAPK-IN-1 is a potent dual inhibitor of the NF-κB and MAPK pathways with potential anti-inflammatory activity, inhibition of NO production, and inhibition of LPS-induced activation of iNOS, COX-2, ERΚ and P38. NF-κB/MAPK-IN-1 is used for the prevention and treatment of rheumatoid arthritis (RA).

PROTAC CDK12 13 Degrader-1 (7f) is a potent and selective dual degrader of the cell cycle protein-dependent kinases CDK12 (DC50: 2.2 nM) and CDK13 (DC50: 2.1 nM), used in the context of breast cancer.

PD-1/PD-L1-IN-13 is a potent immune checkpoint PD-1/PD-L1 inhibitor with an IC50 value of 10.2 nM for PD-1/PD- L1 interaction.PD-1/PD-L1-IN-13 promotes CD8+ T-cell activation and delays tumour growth in a Hepa1-6 homozygous mouse model.

ERK2 p38α MAPK-IN-1 (Compound 1, In silico Hit-2), a selective inhibitor of ERK2 and p38α MAPK, exhibits potent activity with an IC 50 of 82 μM against ERK2. It uniquely binds to the allosteric sites of both ERK2 and p38α MAPK. This compound is utilized for type 2 diabetes research [1].

Nociceptin (1-13), amide TFA, a potent ORL1 receptor (opioid receptor-like 1 receptor, OP4) agonist, exhibits a pEC50 of 7.9 in mouse vas deferens and a Ki of 0.75 nM for rat forebrain membrane binding [1] [2].

PARP-1-IN-13 (Compound 19c) is a potent PARP-1 inhibitor with an IC50 of 26 nM, hindering DNA single-strand break repair and exacerbating double-strand breaks, leading to apoptosis in cancer cells via the mitochondrial pathway [1].

Cortistatin-29 (1-13) is a neuropeptide and cleavage product of cortistatin-29 , which is a cleavage product of procortistatin. Cortistatin-29 (1-13) corresponds to the first 13 amino acids of cortistatin-29.

Selective and competitive nociceptin receptor antagonist, devoid of any agonist activity. Binds selectively to recombinant nociceptin receptors (pKi = 8.4), and competitively antagonizes the actions of nociceptin in vitro and in vivo.

Dynorphin B (1-13), a 13 amino acid, is an extraordinarily potent opioid peptide.

ACTH (1-13) is a 13-aa peptide with cytoprotective effects in a model of ethanol-induced gastric lesions in rats. Adrenocorticotropic hormone (ACTH), also known as corticotropin, is produced and secreted by the anterior pituitary gland and plays a critical role in the hypothalamic-pituitary-adrenal axis in response to biological stress.

Potent agonist of the nociceptin (ORL1) receptor, demonstrated both in vitro and in vivo. Selective, competitive antagonism at the nociceptin receptor has also been reported (pA2 = 7.02 and 6.75 in the guinea pig ileum and mouse vas deferens respectively)

[DAla2] Dynorphin A (1-13), amide (porcine) is a peptide that potentially acts as a κ opioid receptor agonist, used in nervous system research [1].